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Purpose: Haploinsufficiency of USP7, located at chromosome
16p13.2, has recently been reported in seven individuals with
neurodevelopmental phenotypes, including developmental delay/
intellectual disability (DD/ID), autism spectrum disorder (ASD),
seizures, and hypogonadism. Further, USP7 was identified to
critically incorporate into the MAGEL2-USP7-TRIM27 (MUST),
such that pathogenic variants in USP7 lead to altered endosomal F-
actin polymerization and dysregulated protein recycling.
Methods: We report 16 newly identified individuals with
heterozygous USP7 variants, identified by genome or exome
sequencing or by chromosome microarray analysis. Clinical
features were evaluated by review of medical records. Additional
clinical information was obtained on the seven previously reported
individuals to fully elucidate the phenotypic expression associated
with USP7 haploinsufficiency.
Results: The clinical manifestations of these 23 individuals suggest
a syndrome characterized by DD/ID, hypotonia, eye anomalies,
feeding difficulties, GERD, behavioral anomalies, and ASD, and
more specific phenotypes of speech delays including a nonverbal
phenotype and abnormal brain magnetic resonance image findings
including white matter changes based on neuroradiologic examina-
tion.
Conclusion: The consistency of clinical features among all
individuals presented regardless of de novo USP7 variant type
supports haploinsufficiency as a mechanism for pathogenesis and
refines the clinical impact faced by affected individuals and
caregivers.
Genetics inMedicine (2019) 21:1797–1807; https://doi.org/10.1038/s41436-
019-0433-1
Keywords: USP7; neurodevelopment; speech delay; white matter
paucity; corpus callosum thinning
INTRODUCTION
De novo heterozygous loss-of-function pathogenic variants in
the gene ubiquitin-specific protease 7 (USP7, also called
herpes virus-associated ubiquitin-specific protease, HAUSP),
were recently identified in seven individuals with a novel
neurodevelopmental disorder, manifesting intellectual dis-
ability, autism spectrum disorder (ASD), and seizures.1 Six of
these individuals had genomic heterozygous deletions invol-
ving USP7. One more individual with a nonsense variant of
USP7 had a similar phenotype, indicating a haploinsufficiency
disease model.
Located at chromosome 16p13.2, USP7 encodes a deubi-
quitinating proteolytic enzyme that can cleave multiple
ubiquitin chain linkages.2–4 Previously, USP7 was shown to
regulate ubiquitination of proteins including the MDM2-p53
pathway, important for DNA repair, transcription, and
cancer.2,3
USP7 was reported to function in the endosomal protein
recycling pathway via its incorporation into the MAGEL2-
USP7-TRIM27 (MUST) complex.1,5 USP7 was found to
promote ubiquitination of the actin nucleation promoting
factor WASH by preventing TRIM27 autoubiquitination and
subsequent degradation, while simultaneously limiting
WASH ubiquitination through direct deubiquitination of
WASH.1 USP7’s dual function allows the fine-tuning of
WASH activity, maintaining an appropriate level of endoso-
mal F-actin and a homeostatic balance for retromer-
dependent protein recycling.1,5,6
Here we report 16 newly identified individuals with de novo
pathogenic variants in USP7. Among these, we present two
individuals with a deletion of USP7, three individuals with
nonsense variants, three with splice-site variants, and eight
with missense variants. We also provide expanded clinical
information on the seven previously reported individuals.
MATERIALS AND METHODS
Individuals with USP7 pathogenic variants were enrolled
based on genotype. Identification of patients 1–6 and 9 was
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described previously (patients 1–5 have retained the same
labels; patient 6 was previously labeled subject 7; patient 9 was
previously labeled subject 6) (ref. 1). The 16 newly identified
probands were identified by clinical genome sequencing or
exome sequencing (ES) or chromosomal microarray (CMA)
(coordinates based on build hg19). Upon identification of a
probable pathogenic variant or deletion of USP7, genetic
counselors/physicians from the respective laboratories and
institutions contacted the referring providers, informing them
of a research interest in C.P.S.’s laboratory. Individuals were
either placed in contact with M.D.F. and C.P.S. upon
molecular genetic confirmation of a pathogenic variant of
USP7, referred to them via the Foundation for USP7-Related
Diseases contact pages (www.USP7.org), or identified and
enrolled through GeneMatcher. One individual was identified
via a personal blog post describing primary clinical manifes-
tations and molecular genetic testing results.
An initial phenotypic assessment was obtained of all newly
identified and molecularly confirmed individuals harboring
pathogenic variants/deletions of USP7 (patients 1–23 pre-
sented in Tables S1–S4). Patients 18 and 20 harbor additional
variants in TMEM106B and SLC2A1, respectively, but were
nonetheless enrolled. Likewise, patient 19 also has a de novo
heterozygous 102.5-kb mosaic loss of uncertain significance at
10q21.1 but was also enrolled. Upon consent to share clinical
information, all were contacted for a detailed review of
medical and family history, developmental milestones, and
physical features. Medical records were reviewed as compre-
hensively as possible. Written informed consent was obtained
for use of medical history, genetic testing report, and
photograph (if applicable), as approved by the Baylor College
of Medicine Institutional Review Board.
Statistical analysis of corpus callosum biometry (further
discussed below) was performed by calculating age-based
domain-specific Z-scores for all cases using available norma-
tive data. To evaluate differences between children with USP7
variants and normative data, a one-sample Z-test was used to
determine if the mean Z-score for the cases differed from the
normative mean of zero. Differences were considered
statistically significant if P < 0.05. All statistical analyses were
conducted using Stata version 15 (College Station, TX).
RESULTS
Here we present 16 newly identified individuals with a novel
neurodevelopmental disorder, all of whom have molecularly
confirmed heterozygous de novo variants in USP7. We also
provide expanded clinical information on the seven pre-
viously reported individuals.1 All individuals’ behavioral and
physical characteristics are summarized in Table 1; subjects’
genomic information is provided in Table 2. Each individual’s
clinical phenotype is provided in Tables S1, S2, S3, and S4.
Behavioral characteristics
All individuals with USP7 variants have prominent speech
delays. Moreover, 18% of individuals are currently nonverbal
(patient 4, 10 years old; patient 13, 8 years old; patient 15, 4
years old; and patient 17, 20 years old). Regarding motor
milestones, on average, affected children sat independently at
14 months (range: 4–36 months) and walked at 35 months
(range: 17–156 months, patient 15 not walking).
Of those with formal evaluation, intellectual disability
severity ranged from borderline intellectual functioning (with
one patient reporting a standardized intelligence quotient
[IQ] score in the 80s) to mild–moderate intellectual disability
(with one patient reporting a standardized IQ score of 52, and
one reporting a standardized nonverbal IQ test score of 74).
An additional six patients had not been formally evaluated or
did not have results available but were noted to require special
education.
Of the 17 individuals with available data, five were formally
diagnosed with ASD, with an additional four described to
manifest autistic features.
Four of seven individuals were previously identified to have
aggressive behaviors by their referring physician.1 Further
evaluation of previously identified and new patients identified
an expanded behavioral profile to include impulsivity,
compulsivity, stubbornness, manipulative behaviors, and a
propensity for temper tantrums and aggressive behaviors in
12 of 21 individuals. Additionally, attention-deficit hyper-
activity disorder (ADHD) was present in 6 (4 diagnosed, 2
with signs) of 16 individuals.
Physical characteristics
While 18 of 20 individuals have facial dysmorphisms,
including deep-set eyes and a prominent nasal septum
extending below the alae nasi, these features are variable
and do not currently represent a recognizable dysmorphic
condition (Fig. 1). Seven of 16 individuals manifest hypogo-
nadism (5 males with cryptorchidism and/or micropenis, and
2 females with delayed development of secondary sex
characteristics). Twelve of 22 have a history of feeding
problems, and 8 of 16 report gastroesophageal reflux disease
(GERD). Ten of 22 report seizures. Upon radiologic
examination, 11 of 15 individuals manifested abnormal brain
magnetic resonance imaging (MRI) results, further discussed
below.
Molecular characteristics
All 23 individuals reported here have molecularly confirmed
de novo heterozygous deletions/variants involving USP7
(Table 2). Eight individuals, six previously described,1 have
deletions of chromosome 16 including all or part of USP7,
detected by CMA or genome sequencing. Four individuals,
one previously reported,1 have nonsense variants in USP7,
identified via ES. Eight newly identified individuals have
missense variants in USP7, and three newly identified
individuals have splice-site variants in USP7, all identified
via ES.
Deletion of USP7
Eight individuals harbor whole or partial deletions of USP7
(Fig. 2a, Table 2). Patients 1–6 were reported previously, and
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patients 7 and 8 are newly identified individuals. All eight
manifest DD/ID and speech delays; one is nonverbal.
Strikingly, seven of eight manifest a characteristic behavioral
profile, and seven of seven individuals (five previously
reported and two newly identified) manifest ASD or autistic
features. Though ASD was previously endorsed for patients 2,
4, and 5, upon further chart review they were found only to
exhibit autistic features (Table 1). Of note, patient 1 was
previously reported not to have aggressive behavior, but after
further review was found to exhibit the characteristic
behavioral phenotype. Additionally, patient 3 was previously
reported to demonstrate aggressive behavior but upon
additional review was found only to show some signs of the
behavioral phenotype.1
Six of eight individuals manifest eye anomalies, specifically
myopia, esotropia, and strabismus, and four of six show
dysmorphic facial features. Five of seven manifest hypogo-
nadism; specifically, four males show cryptorchidism and/or
micropenis, and one female shows delayed development of
secondary sex characteristics and no regular menses.
Though only one of six individuals was noted to have
neonatal hypotonia, four of seven manifested hypotonia at the
time of exam (though patient 4 had low-normal tone). Subject
3 was previously reported not to manifest hypotonia;
however, further examination of her chart and physical
history did reflect hypotonia.1 Interestingly, patient 8 was
reported to manifest hypertonia.
Three of four individuals showed gross neurologic aberra-
tions/alterations based upon MRI, characterized by a paucity
of white matter and atypical corpus callosum, and four of
eight manifested seizures.
Nonsense variants in USP7
Four individuals have nonsense variants in USP7 (Fig. 2b,
Table 2). Patient 9 was previously reported as subject 6
(ref. 1); all others are newly identified. Patients 9 and 10 have a
nonsense pathogenic variant, patient 11 has a frameshift
insertion, and patient 12 has a frameshift deletion. All
manifest DD/ID and speech delays (though all are verbal),
and one of three manifests the characteristic behavioral
profile; however, none shows ASD or ADHD.
All four individuals had hypotonia neonatally and at the
time of exam, eye anomalies, and dysmorphic facial features.
Two of the four manifest feeding difficulties requiring
assistance; in addition, patient 9 had decreased fetal move-
ment and infantile lethargy, difficulty gaining weight, chronic
constipation, and GERD. However, the true prevalence of
these characteristics is unclear, as information for the above
difficulties was unavailable for several of the three other
patients.
Neuroradiologic examination showed abnormalities in one
of three patients; patient 9 showed decreases in white matter,
patients 10 and 12 showed no MRI anomalies, and patient 11
has not had MRI performed. Two of four individuals reported
seizures.
Missense variants in USP7
Of the 23 total individuals, 8 (2 males, 6 females) have
missense variants in USP7 (Fig. 2b, Table 2). All eight
manifest speech delays, with three being nonverbal. Seven of
eight manifest DD/ID. Two of seven manifest the character-
istic behavioral profile. One of three assessable individuals
manifests ASD, and one additional individual shows autistic
features. One of four manifests ADHD.
Five of seven manifested hypotonia at the time of exam,
while four of seven manifested neonatal hypotonia. Seven of
Table 2 Genomic information for each subject
Subject Variant coordinates
(hg19)
Variant type Inheritance
Patient 1 (Hao
et al.,1 subject 1)
del(16)(p13.3p13.2)
4868744-9611741
Deletion De novo
Patient 2 (Hao
et al.,1 subject 2)
del(16)(p.13.2)
9051188-9142810
Deletion De novo
Patient 3 (Hao
et al.,1 subject 3)
del(16)(p13.3p13.2)
5752801-9017367
Deletion De novo
Patient 4 (Hao
et al.,1 subject 4)
del(16)(p13.3p13.2)
5426430-9169448
Deletion De novo
Patient 5 (Hao
et al.,1 subject 5)
del(16)(p.13.2)
8969652-9237005
Deletion De novo
Patient 6 (Hao
et al.,1 subject 7)
del(16)(p13.3p13.2)
8954155-9234037
Deletion De novo
Patient 7 del(16)(p.13.2)
8969780-9211161
Deletion De novo
Patient 8 del(16)(p13.2)
9085733-9054621
Intragenic
deletion
De novo
Patient 9 (Hao
et al.,1 subject 6)
c.429C>G; p.Y143* Nonsense De novo
Patient 10 c.1728T>A; p.C576* Nonsense De novo
Patient 11 c.1737dup; p.G580fs Frameshifting
indel
De novo
Patient 12 c.2169_2170delAG;
p.R723fs
Frameshifting
indel
De novo
Patient 13 c.2297T>C; p.I766T Missense De novo
Patient 14 c.675 G>A; p.M225I Missense De novo
Patient 15 c.1117C>T; p.L373F Missense De novo
Patient 16 c.1175G>A; p.G392D Missense De novo
Patient 17 c.3238G>A; p.
D1080N
Missense De novo
Patient 18a c.1454T>G; p.V485G Missense De novo
Patient 19b c.1033G>A; p.E345K Missense De novo
Patient 20c c.2270T>C; p.L757P Missense De novo
Patient 21 c.3202+1G>T Splice-site De novo
Patient 22 c.3202+1G>T Splice-site De novo
Patient 23 c.383+1G>A; p.
E83Hfsd
Splice-site De novo
All variants based on NM_003470.2.
aPatient also has a variant in TMEM106B.
bPatient also has a de novo heterozygous 102.5-kb mosaic loss of uncertain sig-
nificance at 10q21.1.
cPatient also has a de novo pathogenic variant in SLC2A1 (c.376C>T; p.R126C).
dProtein change was confirmed by messenger RNA (mRNA) sequencing.
ARTICLE FOUNTAIN et al
1800 Volume 21 | Number 8 | August 2019 | GENETICS in MEDICINE
seven manifest characteristic facial features, and four of the
eight manifest eye anomalies, namely strabismus, nystagmus,
and aniscoria. Four of the eight were reported to have feeding
difficulties requiring assistive techniques, with five of seven
individuals having difficulty gaining weight, four of six
reporting GERD, and two of five manifesting chronic
diarrhea. Four of four individuals have an abnormal gait.
Two of four manifest features of hypogonadism, with one
male manifesting cryptorchidism and one female manifesting
labial hypoplasia.
Fig. 1 Facial appearance of patients with haploinsufficiency of USP7.While most individuals have facial dysmorphisms, including deep-set eyes and a
prominent nasal septum, extending below the alae nasi, the dysmorphic features present across a varied spectrum and do not represent a recognizable
dysmorphic condition at this time. (a) Patient 3. (b) Patient 7. (c) Patient 8. (d) Patient 10. (e) Patient 11. (f) Patient 13. (g) Patient 14. (h) Patient 15. (i)
Patient 16. (j) Patient 17. (k) Patient 18. (l) Patient 19. (m) Patient 21. (n) Patient 22.
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Neuroradiologic examination identified MRI anomalies in
seven of seven individuals; all showed decreased white
matter, and patient 19 also manifested hydrocephalus ex
vacuo and ventriculomegaly. Three of seven individuals
have a history of seizures.
Splice-site variants in USP7
Three newly identified individuals (all male) have splice-site
variants in USP7 (Fig. 2b, Table 2). Individuals 22 and 23 are
siblings. All manifest DD/ID and speech delays, though all are
verbal (Table 1). Two of the three show the characteristic
behavioral profile as well as ADHD features, though none
manifests ASD.
All show dysmorphic facial features, one of three manifests eye
anomalies (strabismus), and one of three manifested hypotonia
at the time of exam but none reported hypotonia neonatally.
Two of three manifest feeding problems, though none reported
associated problems such as neonatal poor suck, GERD, chronic
constipation, chronic diarrhea, or difficulty gaining weight; in
contrast, all three individuals show excessive weight gain. Two of
three also reported sleep disturbances and asthma.
One individual manifests kyphosis and the two others manifest
scoliosis. None shows hypogonadism or cryptorchidism.
One individual (patient 22) of the three reported suspected
seizures. Only one patient (23) had MR imaging performed,
which was reported to be normal.
Chromosome 16 16p13.3
Subject 1 (1)*
Subject 2 (2)*
Subject 5 (5)*
p.M225I p.G392D p.V485G
p.G580fs
p.C576* p.R723fs
p.L757P
p.I766T
p.D1080N
p.L373F
p.E345K
p.Y143*
b
a
TRAF
1 209 565 1102
USP7 CD HUBL 1–5
Subject 6 (7)*
Subject 7
Subject 8
Subject 3 (3)*
Subject 4 (4)*
p13.2
GLYR1
TMEM114 C16orf72
METTL22
ABAT
TMEM186
PMM2
CARHSP1
USP7
UBN1
PPL
SEC14L5
NAGPA
C16orf89
ALG1
EEF2KMT
Telomere 5,000,000 6,000,000 7,000,000 8,000,000
RBFOX1
9,000,000
Fig. 2 USP7 deletions and point variants. (a) USP7 whole and partial gene deletions in eight individuals, six of which were previously reported, identified
via chromosomal microarray (CMA) or genome sequencing. Asterisks denote previously described individuals; labels used in the previous report are indicated
by numbers in parentheses.1 Newly identified individuals are formatted in bold. Blue and green bars show the position of the deletions. Genomic
coordinates are based on the Human Genome Assembly hg19. (b) Nonsense variants, frameshifting indels, and missense variants in USP7. Two individuals,
one of whom was previously reported, have nonsense variants in USP7. Two newly identified individuals have frameshifting indels of USP7. Eight newly
identified individuals have missense variants in USP7. Bolded variants indicate newly identified individuals; the nonbolded variant indicates a previously
reported case. All variants based on NM_003470.2. In addition, three newly identified individuals with splice-site variants in USP7 are reported in the
manuscript, which are not represented visually in this figure.
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Neuroradiologic examination
Brain MRI analysis and/or chart review identified
neuroradiologic anomalies in 11 of 15 individuals, with
primary features of decreased white matter and thinning of
corpora callosa. Specifically, chart review of four individuals
(2, 5, 9, and 19) noted neuroradiologic anomalies via MRI
to include decreased white matter; in addition, periven-
tricular leukomalacia was noted in patient 5. Chart review of
MRI analysis for patients 4, 10, 12, and 23 noted no
abnormalities. The imaging for these eight individuals was
not available for secondary analysis. MR imaging and
results for seven more individuals (3 and 13–18), ranging in
age at imaging from 4 weeks to 17 years of life, were
made available and secondarily analyzed by an independent
pediatric neuroradiologist (Fig. 3). Analysis included
biometry of the corpus callosum for all individuals except
for patient 13 (as a digital ruler was not provided with
the images) and comparison with age-matched reference
values7 (Table S5). Though a spectrum of findings was
noted, overall there appeared to be a generalized paucity
of white matter with or without white matter T2 hyperinten-
sities. Of note was marked symmetry to the hemispheres of
all the children examined with a shallow pattern to the
gyri. In addition, the splenium and body of the corpus
callosum were generally thin, with varying degrees of
dysmorphism.
Variation in head size and shape
No two patients presented with identical MRI findings. Of the
seven patients with available scans, four had dysmorphic head
shape. Patient 16 (27 months at time of scan; Fig. 3f) showed
mild brachycephaly, patient 14 (17 months at time of scan;
Fig. 3d) showed microcephaly, and patient 13 (31 months at
time of scan; Fig. 3c) showed signs of plagiocephaly.
Conversely, patient 17 (Fig. 3g) showed minor macrocephaly
(34 weeks’ gestation + 4 weeks of life at time of scan).
Shallow gyri patterns
Gyral patterns were notably simplified in patient 14 and
patient 17. Of note was a lack of gyral folding in the gyri of
patient 17. Patient 3 (8 years of age at time of scan; Fig. 3b)
also had slightly reduced sulci and gyri, but not to the degree
of patients 14 and 17.
Symmetry of brain hemispheres
All seven patients scanned had notable symmetry between left
and right hemispheres. Symmetry is more evident in some
patients than in others.
Dysmorphic ventricular system
In addition to external brain structures, structural abnormalities
were identified internally as well. In patients 3, 13, and 16, subtle
abnormalities in the shape of the ventricular systems were
found. Patient 3 showed slightly enlarged lateral ventricles
generally, patient 13 showed an enlarged third ventricle, and
patient 16 had slightly dysmorphic frontal horns.
General paucity of white matter, impacting corpus callosum
White matter paucity is the most common MRI finding in
patients with USP7 pathogenic variants. Corpus callosum size
is a reliable way to judge general myelination and presence of
white matter throughout the brain.8 Corpus callosum fronto-
occipital diameter (FOD), anteroposterior diameter (APD),
genu thickness (GT), isthmus thickness (IT), splenium
thickness (ST), body thickness (BT), and APD/FOD ratio
were measured following procedures described elsewhere and
compared with age-matched reverence values.7 Note that data
for patient 18 (17 years of age at time of scan) are compared
with reference values for 15-year-old-children because
reference values for older children are not available. APD
was significantly smaller in this cohort, with a mean Z-score
± standard deviation of −1.16 ± 1.17 (p= 0.0144). Likewise,
ST and BT were significantly decreased, showing Z-score
means of −0.98 ± 0.82 (p= 0.0034) and −1.18 ± 0.63 (p <
0.0001), respectively. FOD also trended small but comparison
with reference values did not reach statistical significance.7 Of
note, Z-scores fell more than two standard deviations below
the mean for FOD, APD, and BT measures in patient 16, and
for APD and IT measures in patient 18 (17 years of age at
time of scan; Fig. 3h), indicating severe corpus callosum
dysmorphism. The FOD measurement for patient 14 was also
more than two standard deviations below the mean.7
Additionally, patient 3, patient 13, and patient 15 (5 years of
age at time of scan; Fig. 3e) all had larger total white matter
tracts in the corpus callosum. However, unlike normal corpus
callosum anatomy (Fig. 3a), the splenium was smaller than, or
equal to, the size of the body and genu of the corpus callosum.
White matter hyperintensities, including patterns
resembling leukodystrophy
Three of seven patients showed significant white matter
hyperintensities. Patient 14 showed multifocal white matter
hyperintensities in both frontal and occipital/parietal lobes.
Patients 17 and 18 both had frank signal abnormalities that
appeared to look much like leukodystrophy, though patient 18
has an additional variant of TMEM106B, pathogenic variants
in which are known to cause hypomyelinating leukodystro-
phy.9 These hyperintensities were the most widespread
internal structural abnormalities noted in the scans.
DISCUSSION
Here, we expand and delineate the physical, cognitive, and
behavioral phenotypic spectrum of 16 new and 7 previously
reported individuals with heterozygous de novo pathogenic
variants of the gene USP7. The consistency of clinical
features among all individuals, regardless of variant type,
supports the pathogenicity of these variants and haploin-
sufficiency as a pathomechanism for USP7-related disor-
ders, and suggests that reverse phenotyping is possible.
Compared with our previously reported findings, the
present study confirms the high prevalence (>50%) of
DD/ID, ASD, and hypotonia, but shows that seizures and
hypogonadism are relatively less common (<50%). Here we
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also clarify the characteristic behavioral profile and expand
the phenotype to encompass speech delays including a
nonverbal phenotype, feeding difficulties, GERD, and eye
anomalies (such as myopia, estropia, strabismus, and
nystagmus). We also broaden the phenotype to include
white matter changes on brain MRI, including paucity of
white matter, thinning of the corpus callosum, and
occasional T2 hyperintensities.
USP7 has been shown to regulate the ubiquitination of a
variety of proteins with varying functional diversity. Indeed,
USP7 has been implicated in transcription, DNA repair,
immune response, and cancer, including the MDM2-p53
mediated pathway.2,3 Interestingly, conditional knockout of
Usp7 in the mouse brain resulted in neonatal lethality.10
Moreover, this lethality was not rescuable by the knockout of
p53, suggesting a p53-independent neural function. To date,
no individuals homozygous null for USP7 have been
identified, further supporting a putative critical neuronal
function of USP7.
Previously, we reported USP7 to incorporate into the
MAGEL2-TRIM27 ubiquitin ligase complex. This complex
allows for USP7 to maintain optimal activity of the WASH
complex, endosomal F-actin levels, and subsequent protein
recycling.1 Importantly, the modification of any of these
complexed molecular interactors leads to alterations in
proper function of endosomal protein recycling. Indeed,
TRIM27 was previously implicated in ASD, while truncating
variants in the paternal copy of the maternally imprinted
gene MAGEL2 lead to Schaaf–Yang syndrome (SHFYNG), a
novel neurodevelopmental disorder.11,12 Moreover, absence
of a larger paternally expressed region that contains
MAGEL2, 15q11-q13, causes another neurodevelopmental
disorder, Prader–Willi syndrome (PWS).13 The clinical
phenotypes associated with USP7 variants show marked
overlap with those of both SHFYNG and PWS; all show a
high prevalence of DD/ID, hypotonia, and feeding difficul-
ties, as well as dysmorphic facial features, eye anomalies
(including estropia and myopia), and small hands and
feet.12–15 Though the major diagnostic criteria for PWS
delineate the characteristic facial features as including
almond-shaped eyes, a small-appearing mouth with down-
turned corners and a thin upper lip, and dolichocephaly in
infancy,15 dysmorphic facial features in SHFYNG and
USP7-related disorders are variable and inconsistent.
Despite the overlapping characteristics, each disorder
remains distinct. Common features specific to individuals
with USP7 pathogenic variants include a characteristic
behavioral phenotype and brain MRI anomalies including a
paucity of white matter. Furthermore, these individuals do not
display excessive weight gain at a prevalence as high as in
PWS (16% vs. 66.7%) and do not seem to typically exhibit the
hyperphagia present in 84.4% of individuals with PWS, nor
do they manifest ASD at a prevalence as high as in SHFYNG
(53% vs. 77%); likewise, these individuals also display a lower
prevalence of hypogonadism compared with both PWS and
SHFYNG (44% vs. 51% vs. 73%) (refs. 12,15). Moreover, of
particular note, while the prevalence of contractures in
individuals with SHFYNG exceeds 80% (ref. 12), only 25%
of individuals with USP7 variants (4/16, two with a deletion
and two with a nonsense variant) manifested contractures.
Furthermore, though all three disorders are associated with
speech delays,16–18 the prevalence of a nonverbal phenotype
appears greater in SHFYNG (43%) and in USP7-related
disorders (18%) than in PWS.
a b c
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Fig. 3 Brain abnormalities encountered in patients with pathogenic variants in USP7. Age at imaging ranged from full-term corrected to 17 years of
life. Though a spectrum of findings was found, the splenium appeared smaller in all children with varying degrees of thinning and dysmorphism to the body
of the corpus callosum. Overall, there appeared to be a generalized paucity of white matter with or without white matter T2 hyperintensities. Of note was
marked symmetry to the hemispheres of all the children examined with a shallow pattern to the gyri. (a) Normal magnetic resonance image (MRI) for
comparison. (b) Patient 3 (at 8 years). (c) Patient 13 (at 31 months). (d) Patient 14 (at 17 months). (e) Patient 15 (at 5 years). (f) Patient 16 (at 27 months).
(g) Patient 17 (at 34 weeks’ gestation + 4 weeks of life). (h) Patient 18 (at 17 years).
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As noted, 11 of the 15 individuals harboring a pathogenic
variant in USP7 who had an MRI performed manifested
abnormal brain morphology consisting of a paucity of white
matter and alterations to gross brain structure. Globally, brain
morphology is affected in the forms of micro- and
brachycephaly, simplified gyral patterns, and brain hemi-
sphere symmetry. Specific findings included a paucity of
white matter in deep and subcortical regions, thinning of the
corpus callosum, and abnormally shaped ventricular systems
of the central nervous system.
As with USP7 pathogenic variants, PWS is likewise
associated with ventriculomegaly19 and white matter
changes,20–22 including white matter lesions.23 Biometry
measurements are not available for comparison, though
interestingly, altered white matter microstructure (measured
by fractional anisotropy) has been noted in PWS areas
including the corpus callosum21 and specifically in the
splenium.22 However, rather than simplified or absent gyral
folding, polymicrogyria has been found in individuals with
PWS.19 In addition, though corpus callosum thinning is
characteristically caused by genetic and metabolic disorders as
well as disruptions in neurodevelopment,8,24 agenesis/hypo-
plasia of the corpus callosum is a relatively uncommon (<3%)
finding in PWS.25 Thus, despite some overlap, the constella-
tion of MRI findings associated with USP7 pathogenic
variants differs from that of PWS. Though formal evaluation
of brain morphology in SHFYNG has not yet been conducted,
preliminary assessment of patients with SHFYNG show that
white matter abnormalities are not evident to the degree seen
in patients with USP7 variants. It appears that abnormalities
in white matter help further distinguish the phenotype of
USP7 variants from that of truncating variants in MAGEL2
causal to SHFYNG.
While pathogenic variants of USP7 are consistently
correlated with white matter and corpus callosum anomalies
identified via MRI, along with the physical and behavioral
characteristics described above, phenotype-first diagnosis
remains unlikely. Ascertainment bias, unstandardized pheno-
typing, a small sample size, and varying patient ages are
limitations for the findings presented here. Furthermore, an
individual’s age and IQ can affect whether certain potential
diagnoses and features are relevant, such as ASD, character-
istic behaviors, and hypogonadism. Additionally, while it is
plausible that patient 18’s USP7 variant led to his white matter
and corpus callosum anomalies, the possibility of his
TMEM106B variant contributing to these MRI findings
should also be considered, given this gene’s association with
hypomyelinating leukodystrophy.9 Whether the variant in
TMEM106B acts in conjunction with the loss of USP7
function has yet to be explored. Furthermore, patient 20
harbors an additional de novo pathogenic variant in SLC2A1,
associated with several overlapping features including DD/ID,
absent speech, seizures, and aggressive behavior,26 likewise
raising the possibility of a dual diagnosis or multiple-variant
compound effects.
Proper assessment of patients with complicated neurologic
and physiological abnormalities including hypotonia, DD/ID,
ASD, hypogonadism, and speech delay can be difficult,
considering the phenotypic overlap with other known
neurodevelopmental disorders like PWS and SHFYNG.
USP7-associated neurodevelopmental disorder represents a
novel genetic syndrome with features similar to both
SHFYNG and PWS. Defining features of individuals with
pathogenic variants/deletions of USP7 include severe speech
delay, unique MRI anomalies, seizures in 48% of individuals,
and a lack of high prevalence of the contractures typically
observed in SHFYNG. Characteristic MRI findings (e.g., white
matter paucity, corpus callosum thinning, etc.) may provide a
key piece of evidence to raise clinical suspicion of USP7-
associated neurodevelopmental disorder.
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